Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.30 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
| ▸ | CCND2 | P30279 | 1/20 | 0.30 |
| ▸ | CCND3 | P30281 | 1/20 | 0.30 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6629152 | 0.78 | FAAH (0.32) | — | |
| SCHEMBL9004255 | 0.78 | CDK2 (0.35) | CDK2 | |
| SCHEMBL9963871 | 0.75 | CDK2 (0.34) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL5724820 | 0.74 | — | — | |
| SCHEMBL18245550 | 0.73 | — | — | |
| SCHEMBL18857313 | 0.67 | CDK2 (0.32) | CDK2 | |
| SCHEMBL12263976 | 0.67 | CDK2 (0.32) | CDK2 | |
| SCHEMBL2616422 | 0.67 | CDK2 (0.35) | CDK2 | |
| SCHEMBL2619433 | 0.67 | PIK3CG (0.41) | CDK2 | |
| SCHEMBL13545977 | 0.65 | ALDH1A1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087951-B9 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1087951-B1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2005-02-09 | — | — | EP | disclosed |
| US-6720347-B2 | SUCH AS ETHYL-3-((E)-2-ACETAMIDO-THIAZOL-5-YL)-ACRYLATE FOR TREATMENT OF CANCER, PROLIFERATIVE DISEASES, INFLAMMATION, AND ARTHRITIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | RAWLINS DAVID B (US) | 2002-11-07 | — | — | US | disclosed |
| US-6407124-B1 | ANTICARCINOGENIC, ANTIPROLIFERATIVE, ANTIINFLAMMATORY, AND ANTIARTHRITIC AGENTS; ALZHEIMER*S DISEASE AND CARDIOVASCULAR DISORDER TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | CCNK, CDK2, CCNL2 | CDK2 2/4885CCNE2 23/4885CCNE1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.